Lead Exposure and Prevention Advisory Committee

AGENCY:

Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION:

Notice of meeting.

SUMMARY:

In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Lead Exposure and Prevention Advisory Committee (LEPAC). This meeting is open to the public by teleconference but advance registration by November 19, 2021 is needed to receive the information to join the meeting. The registration link is https://www.zoomgov.com/webinar/register/WN_qeMSB7npRJ23PTV6t1KMtQ.

DATES:

The meeting will be held on December 3, 2021, from 9:00 a.m. to 4:15 p.m., EST.

ADDRESSES:

Register in advance at https://www.zoomgov.com/webinar/register/WN_qeMSB7npRJ23PTV6t1KMtQ to receive the information to join the meeting.

FOR FURTHER INFORMATION CONTACT:

Alexis Pullia, M.P.H., C.P.H., Committee Management Specialist, National Center for Environmental Health, CDC, 4770 Buford Highway, Atlanta, GA, 30341, Telephone: (770) 488-3300; Email: lepac@cdc.gov.

SUPPLEMENTARY INFORMATION:

Purpose: The Lead Exposure and Prevention Advisory Committee was established under Section 2203 of Public Law 114-322, the Water Infrastructure Improvements for the Nation Act; 42 U.S.C. 300j-27, Registry for Lead Exposure and Advisory Committee. The Secretary, Department of Health and Human Services (HHS) and by delegation, the Director, CDC and Administrator, NCEH/ATSDR, are authorized under Section 2203 of Public Law 114-322 (42 U.S.C. 300j-27) to review research and Federal programs and services related to lead poisoning and to identify effective services and best practices for addressing and preventing lead exposure in communities.

The LEPAC is charged with providing advice and guidance to the Secretary, HHS, and the Director, CDC and Administrator, ATSDR, on (1) reviewing Federal programs and services available to individual communities exposed to lead; (2) reviewing current research on lead exposure to identify additional research needs; (3) reviewing and identifying best practices, or the need for best practices regarding lead screening and the prevention of lead poisoning; (4) identifying effective services, including services relating to healthcare, education, and nutrition for individuals and communities affected by lead exposure and lead poisoning, including in consultation with, as appropriate, the lead exposure registry as established in Section 2203 (b) of Public Law 114-322; and (5) undertaking any other review or activities that the Secretary determines to be appropriate.

Matters To Be Considered: The agenda will include updates on the blood lead reference value, lead-related activities from Federal LEPAC Members, the 1988 CLIA Amendment, and from Federal environmental justice efforts focused on lead, a discussion of best practices for increasing and enhancing screening in underserved populations, and presentations on mapping efforts to identify populations at higher risk of lead exposure and Lead Safe Cleveland. Agenda items are subject to change as priorities dictate.

Public Participation

Procedure for Oral Public Comment: The public comment period is scheduled on December 3, 2021 from 11:05 a.m. until 11:20 a.m. Individuals wishing to make a comment during the public comment period, please email your name, organization, and telephone number by November 19, 2021, to LEPAC@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.